Last updated 18 days ago

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

180 patients around the world

Available in Argentina, United States

Eli Lilly and Company

3Research sites

180Patients around the world

This study is for people with

Obesity

Diabetes

Diabetes mellitus type 2

To 75 Years

All Gender

: Have type 2 diabetes.
Have a BMI of ≥27 kilograms per square meter (kg/m2).
Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss).

: Have a prior or planned surgical treatment for obesity.
Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma.
Have poorly controlled hypertension.
Have any of the following cardiovascular conditions within 3 months prior to screening.
Acute myocardial infarction.
Cerebrovascular accident (stroke).
Unstable angina.
Hospitalization due to congestive heart failure.
Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure.
Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes.
Have ongoing or a history of bradyarrhythmias other than sinus bradycardia.
Have renal impairment.
Have a history of symptomatic gallbladder disease within the past 2 years.
Have signs and symptoms of any liver disease.
Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality.
Have a history of acute or chronic pancreatitis.
Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening.

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Av. Pueyrredon 1746, CABA, Buenos Aires

Centro Médico Viamonte SRL - CABA, Buenos Aires

Av. Córdoba 2019, CABA, Buenos Aires

Consultorio de Investigación Clinica EMO SRL

Eduardo Acevedo 42, CABA, Buenos Aires

SponsorEli Lilly and Company

Study typeInterventional

Conditions

ObesityDiabetes mellitus type 2

Requirements

To 75 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06901349